To this end, we tested whether drugs targeting various CRC-promoting mechanisms, e.g. vemurafenib (a RAF inhibitor) [31], selumetinib (a MEK inhibitor) [32], pictilisib (a PI3 kinase inhibitor) [33] or lapatinib [34] (an EGFR/ERBB2 inhibitor) [35], enhance death of DLD1 cells caused by MLKL KO. This evidence concerns the gene ERBB2 and colorectal carcinoma.